Avidity Biosciences, a preclinical biotech developing antibody therapies for muscle disorders, raised $259 million by offering 14.4 million shares at $18, the high end of the upwardly revised range of $17 to $18. Earlier on Thursday, the La Jolla, CA-based company raised the proposed IPO range and the shares on offer to 12 million; it originally planned to offer 10 million shares at $14 to $16. Avidity Biosciences plans to list on the Nasdaq under the symbol RNA. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as lead managers on the deal.
